Three-drug chemo plus targeted therapy for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three chemotherapy drugs plus a targeted therapy as a first treatment for advanced colorectal cancer. The goal is to see if this strong drug mix can shrink tumors better than standard approaches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer (spread to other organs or cannot be removed by surgery).
- You have not had chemotherapy for this advanced cancer before.
- You are in good physical condition (able to do most daily activities yourself).
- Your blood counts and liver/kidney function are within normal limits.
- You do not have severe nerve damage, another active cancer, or a DPYD gene mutation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs, levozolinate and 5-FU, given together as a first treatment for advanced colorectal cancer that cannot be surgically removed. It aims to see if giving them at the same time works better for patients who have never received treatment for this stage of cancer.
This trial tests two different chemotherapy regimens (FOLFOX8 and mFOLFOX6), each paired with a targeted drug (bevacizumab or cetuximab), to treat colorectal cancer that has spread and cannot be surgically removed. The goal is to find which combination works best as a first treatment.
This trial tests whether a functional test on a tumor biopsy can help choose the best first chemotherapy regimen (FOLFOX or FOLFIRI) for people with metastatic colorectal cancer. It aims to improve outcomes by matching treatment to each person's unique tumor biology.
This trial tests whether a combination of three drugs (cetuximabβ, envolimab, and mFOLFOX6) can help people with advanced colorectal cancer that has not been treated before. It is for people whose tumors have certain gene markers (RAS/BRAF wild-type and MSS).
This trial tests a combination of chemotherapy (mFOLFOX6) and a targeted antibody (HLX04), followed by immunotherapy (serplulimab) for people with metastatic colorectal cancer that is MSS or pMMR type and cannot be removed by surgery. It is for those who have not had prior chemotherapy with oxaliplatin, immunotherapy, or targeted therapy for their cancer.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
Hear when a new Neoplasm Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.